Clinical trial · Observational
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Spectroscopy Imaging with rectal probe | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- High risk prostate cancer patients
- description
- Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.
- interventionNames
- Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe
- label
- Low risk prostate cancer patients
- description
- Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 \[3+4\] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.
- interventionNames
- Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe
Primary outcomes (1)
- measure
- Number of participants with increased intraprostatic lipid concentration
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate cancer diagnosis prior to treatment * Age 21 years or older * Signed informed subject consent * Prostatectomy as planned prostate cancer treatment Exclusion Criteria: * Men who do not choose prostatectomy * Men who have undergone any neoadjuvant therapy * Men who have cardiac pacemakers or other implanted electronic devices * Men who have any surgically implanted metal * Men who have had any surgical procedure that precludes placement of endorectal probe * Indication of dementia or memory issues listed on problem list * Men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray * Men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications
References
Publications (0)
Data not yet available